化妆品 国产化妆品 进口化妆品 化妆品原料 VIP 药品名称BI-765063 扩展信息 专利信息
318 -- 2:21 App MDM2-p53 拮抗剂 (BI 907828) 作用机制 241 -- 2:02 App 双特异性抗体-Xentuzumab的作用机制 309 -- 1:16 App DLL3-CD3双特异性抗体作用机制 110 -- 2:35 App KISIMA™癌症疫苗 (ATP-128)作用机制 205 -- 2:03 App SOS1-KRAS 抑制剂 (BI 1701963)- 作用机制 ...
BI 765063是一种针对关键骨髓细胞检查点抑制剂SIRPα的单克隆抗体拮抗剂。BI 765063通过与SIRPα结合从而阻止SIRPα和CD47进行配体结合,进而阻止会导致骨髓细胞中抗肿瘤物质(如巨噬细胞和树突状细胞)降低的细胞信号传输。在2019年3月,OSE Immunotherapeutics获得法国和比利时卫生监管部门的I期临床试验批准,以评估BI 765063...
and OSE Immunotherapeutics SA (ISIN: FR0012127173; Mnemo: OSE) (Paris:OSE) today announce that the first patient has been dosed in the expansion phase of the Phase 1 clinical trial evaluatingBI 765063, a first-in-class monoclonal antibody antagonist of SIRPα, in combination with ezabenlimab...
BI 765063 strongly binds V1 allele, one of the 2 major functional allele of SIRPα expressed in more than 80% of general population and Asian (in 60%). Anti-tumor effect was shown in various in vivo cancer models using the validated anti-mouse SIRPα mAbs surrogate as single agent. The...
Boehringer Ingelheim and OSE Immunotherapeutics SA(ISIN: FR0012127173; Mnémo: OSE) today announce that the first patient has been dosed in the first-in-human Phase 1 clinical trial evaluating BI 765063, formerly OSE-172, a first-in-class monoclonal antibody antagonist of SIRPα, being studied ...